Gene Mutation Spectrum of Malignant Hyperthermia in China
- Conditions
- Malignant Hyperthermia
- Interventions
- Diagnostic Test: gene sequencing
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04474860
- Locations
- π¨π³
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention
Not Applicable
Completed
- Conditions
- Primary PreventionCardiovascular DiseaseStroke
- Interventions
- Other: The strategic use of messages in risk communication
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 13114
- Registration Number
- NCT04450888
- Locations
- π¨π³
Health center of Sipo town, Yibin, Sichuan, China
Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: IMRTRadiation: IMRT and concurrent cisplatin
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 562
- Registration Number
- NCT04414566
- Locations
- π¨π³
Xingchen Peng, Chengdu, Sichuan, China
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer
Phase 2
Not yet recruiting
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04405154
Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Carcinoma, Renal CellFumarate Hydratase DeficiencyImmunotherapy
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT04387500
- Locations
- π¨π³
West China Hospital, Chengdu, Sichuan, China
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
Phase 2
- Conditions
- Advanced CancerMetastatic Kidney CancerNeoadjuvant Therapy
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04385654
Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy
Phase 4
- Conditions
- Hepatitis, AutoimmunePrimary Biliary CholangitisImmunosuppression
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04376528
- Locations
- π¨π³
WestChina Hospital, Chengdu, Sichuan, China
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04318730
- Locations
- π¨π³
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
Phase 2
Recruiting
- Conditions
- Low-grade Glioma
- Interventions
- Radiation: intensity modulated radiation therapy
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT04316039
- Locations
- π¨π³
Xingchen Peng, Chengdu, Sichuan, China
Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy
Not Applicable
Completed
- Conditions
- Primary Liver Cancer
- Interventions
- Drug: 0.9% normal saline
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT04295330
- Locations
- π¨π³
West China Hospital, Chengdu, Sichuan, China
Β© Copyright 2025. All Rights Reserved by MedPath